CTMX - CytomX Therapeutics, Inc.

QQQ $ 431.01 $ 6.55 (1.54 %)

DIA $ 382.27 $ 1.39 (0.36 %)

SPY $ 508.26 $ 4.77 (0.95 %)

TLT $ 88.26 $ 0.46 (0.52 %)

GLD $ 216.60 $ 0.70 (0.32 %)

Previous Close

$ 1.59

Open

$ 1.64

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 1.60 - $ 1.64

52 Week Range

$ 1.04 - $ 2.86

Volume

249,227

Average Volume

Market Cap

117.36M

Beta (5Y Monthly)

$ 1.05

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	03-11-2024	12-31-2023	10-K
2	11-07-2023	09-30-2023	10-Q
3	08-08-2023	06-30-2023	10-Q
4	05-09-2023	03-31-2023	10-Q
5	03-27-2023	12-31-2022	10-K
6	11-08-2022	09-30-2022	10-Q
7	08-04-2022	06-30-2022	10-Q
8	05-05-2022	03-31-2022	10-Q
9	03-01-2022	12-31-2021	10-K
10	11-04-2021	09-30-2021	10-Q
11	08-05-2021	06-30-2021	10-Q
12	05-06-2021	03-31-2021	10-Q
13	02-24-2021	12-31-2020	10-K
14	11-05-2020	09-30-2020	10-Q
15	08-06-2020	06-30-2020	10-Q
16	05-07-2020	03-31-2020	10-Q
17	02-27-2020	12-31-2019	10-K
18	11-07-2019	09-30-2019	10-Q
19	08-07-2019	06-30-2019	10-Q
20	05-09-2019	03-31-2019	10-Q
21	02-27-2019	12-31-2018	10-K
22	11-06-2018	09-30-2018	10-Q
23	08-08-2018	06-30-2018	10-Q
24	05-09-2018	03-31-2018	10-Q
25	03-07-2018	12-31-2017	10-K
26	11-07-2017	09-30-2017	10-Q
27	08-07-2017	06-30-2017	10-Q
28	05-05-2017	03-31-2017	10-Q
29	03-02-2017	12-31-2016	10-K
30	11-03-2016	09-30-2016	10-Q
31	08-03-2016	06-30-2016	10-Q
32	05-06-2016	03-31-2016	10-Q
33	03-07-2016	12-31-2015	10-K
34	11-23-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

JP Morgan Upgrades CytomX Therapeutics to ...
04/22/2024 12:18:44

JP Morgan analyst Anupam Rama upgrades CytomX Therapeutics (NASDAQ:CTMX) from Underweight to Neutral.

12-health-care-stocks-moving-in-wednesdays-after-market-session

12 Health Care Stocks Moving In Wednesday'...
04/10/2024 20:31:09

CytomX Therapeutics Doses First Patient Wi...
04/08/2024 12:22:17

CytomX Therapeutics Announces Milestone Ac...
03/18/2024 12:13:29

- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone paym...

Why Asana Shares Are Trading Lower By 11%?...
03/12/2024 18:07:31

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.

BMO Capital Maintains Market Perform on Cy...
03/12/2024 15:11:32

BMO Capital analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Market Perform and lowers the price targ...

12-health-care-stocks-moving-in-tuesdays-pre-market-session

12 Health Care Stocks Moving In Tuesday's ...
03/12/2024 13:05:56

Wedbush Reiterates Neutral on CytomX Thera...
03/12/2024 12:24:25

Wedbush analyst Robert Driscoll reiterates CytomX Therapeutics (NASDAQ:CTMX) with a Neutral and maintains $3 price target.

Why Oracle Shares Are Trading Higher By Ar...
03/12/2024 12:11:02

Shares of Oracle Corporation (NYSE: ORCL) rose sharply in today’s pre-market trading after the company reported upbeat earning...

12-health-care-stocks-moving-in-mondays-after-market-session

12 Health Care Stocks Moving In Monday's A...
03/11/2024 21:34:44

Recap: CytomX Therapeutics Q4 Earnings
03/11/2024 20:10:12

CytomX Therapeutics Q4 2023 GAAP EPS $0.01...
03/11/2024 20:06:57

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $...

Earnings Scheduled For March 11, 2024
03/11/2024 08:56:22

Companies Reporting Before The Bell • Ballard Power Systems (NASDAQ:BLDP) is estimated to report quarterly loss at $0.13 per s...

CytomX Therapeutics's Earnings Outlook
03/08/2024 15:02:00

12-health-care-stocks-moving-in-tuesdays-intraday-session

12 Health Care Stocks Moving In Tuesday's ...
02/27/2024 17:31:10

CytomX Therapeutics Announces FDA Clearanc...
01/24/2024 13:14:40

- Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 -- I...

CytomX Therapeutics Outlines 2024 Company ...
01/04/2024 13:15:58

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data anticipated in the 2nd half of 2024 - - IND applicatio...

Wedbush Maintains Neutral on CytomX Therap...
11/09/2023 15:41:26

Wedbush analyst Robert Driscoll maintains CytomX Therapeutics (NASDAQ:CTMX) with a Neutral and raises the price target from ...

Wedbush Upgrades CytomX Therapeutics to Ou...
11/08/2023 18:59:56

Wedbush analyst Robert Driscoll upgrades CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Outperform and raises the price t...

CytomX Therapeutics Q3 EPS $0.04 Beats $(0...
11/07/2023 22:35:08

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $...